COMMUNIQUÉS West-GlobeNewswire

Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
10/08/2026
Experienced Merck researcher will expand the Board’s drug discovery expertise MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical [...]
Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint
10/08/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart [...]
Kraig Biocraft Laboratories CEO Kim Thompson Publishes Thought Leadership Article on the Next Chapter of Authored Biology in Biocompare
10/08/2026
Byline Article Introduces "Authored Biology" Framework and Draws on Kraig Labs' Spider Silk Journey to Chart the Future of Biology-Enabled Manufacturing ANN ARBOR, Mich., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft [...]
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program [...]
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology
10/08/2026
Acquisition adds ABS-011, an investigational Phase 2b gallium-68-labeled PET radiodiagnostic tracer targeting HER2 Transaction strengthens Curium radiodiagnostic capabilities and oncology footprint, including in breast [...]
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
10/08/2026
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population, treatment with TNX-103 [...]
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
10/08/2026
Grifols’ SPARTA phase 3 trial is designed to evaluate the clinical efficacy and safety of two separate weekly dose regimens of Grifols’ Prolastin ® -C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients [...]
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
10/08/2026
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 [...]
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
10/08/2026
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and [...]
BrewDog Claims London's Summer Park Season with ‘Park IPA’
10/08/2026
Punk IPA becomes “Park IPA” throughout August as BrewDog celebrates one of London’s most iconic summer traditions – great beer, great friends and sunny afternoons in the park. ELTON, United Kingdom, Aug. 10, 2026 (GLOBE [...]
Grey Matters Appoints Radiologist Dr. Jayson A. Lord, MD as Medical Director of its First Dedicated PET Neuroimaging Clinic in the U.S.
10/08/2026
VANCOUVER, British Columbia, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company” or “ Grey Matters ”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to [...]
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
10/08/2026
SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care Potential [...]
Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
10/08/2026
Neurology Review Software Enhancements Included as Part of Industry-Leading Ceribell Point-of-Care Brain Monitoring System SUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” [...]
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA [...]
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
10/08/2026
Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026 Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK results [...]
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
10/08/2026
TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered [...]
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
10/08/2026
NEW YORK and TOKYO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") today announced a cooperation agreement with PT PARVA CANDELA ("PARVA [...]
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
10/08/2026
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY ® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI ® 2Q 2026 net product [...]
ChemoMetec enters collaboration agreement with Roche Diagnostics
10/08/2026
ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties’ solutions in the field of [...]

Pages